Description: Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Home Page: www.futuramedical.com
FUM Technical Analysis
Surrey Technology Centre
Guildford,
GU2 7YG
United Kingdom
Phone:
44 14 8368 5670
Officers
| Name | Title |
|---|---|
| Mr. James Henry Barder | CEO & Exec. Director |
| Ms. Angela Hildreth | COO, Fin. Director, Company Sec. & Exec. Director |
| Mr. Kenneth William James | Head of R&D & Exec. Director |
| Dr. William Duncan Potter | Chief Scientific Officer & Adviser to the Board |
| Graham Smith | Head of Alliance Partnerships & Supply |
| Kevin Langridge | Head of Quality |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 18.3513 |
| Price-to-Sales TTM: | 4251.2055 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |